CoChat

Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma

Open access
McIntyre, Caitlin A., Lawrence, Sharon A., Richards, Allison L., Chou, Joanne F., Wong, Winston, Capanu, Marinela, Berger, Michael F., Donoghue, Mark T. A., Yu, Kenneth H., Varghese, Anna M., Kelsen, David P., Park, Wungki, Balachandran, Vinod P., Kingham, T. Peter, D’Angelica, Michael I., Drebin, Jeffrey A., Jarnagin, William R., Iacobuzio‐Donahue, Christine A., Allen, Peter J., O’Reilly, Eileen M. · 2020 · Cancer
Cited by 76

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Background: KRAS, TP53, CDKN2A, and SMAD4 are established driver genes in pancreatic ductal adenocarcinoma (PDAC). This study was aimed at determining whether the mutational status of driver genes and those involved in DNA repair pathways are associated with clinical outcomes for individuals who undergo resection. Methods: Eligible individuals were those who underwent resection of PDAC and consented to targeted sequencing of their primary tumor via Memorial Sloan Kettering–Integrated Mutation Profiling of Actionable Cancer Targets (MSK‐IMPACT). Genomic alterations were determined on the basis of MSK‐IMPACT results from formalin‐fixed, paraffin‐embedded samples. Associations between genomic alterations and clinical outcomes were assessed. Results: Targeted sequencing was performed on 283 primary tumors resected between 2004 and 2017. The median follow‐up was 23 months among survivors. Alterations in KRAS and TP53 were associated with worse overall survival (OS) in comparison to wild type (median for KRAS, 38.8 months [95% CI, 33.0‐45.5 months] vs 91.0 months [95% CI, 34.8 months to not available (NA)]; P = .043; median for TP53, 37.4 months [95% CI, 32.1‐42.8 months] vs 65.0 months [95% CI, 33.0 months to NA]; P = .035). KRAS G12D mutations were associated with worse OS (median, 31.6 months [95% CI, 25.3‐45.5 months] vs 39.2 months [95% CI, 37.4‐75.2 months]; P = .012). TP53 truncating mutations (median, 39.6 months [95% CI, 32.4‐75.2 months] vs 33.9 months [95% CI, 24.0‐39.0 months]; P = .020) and those associated with loss of heterozygosity (median, 26.6 months [95% CI, 21.6‐44.2 months] vs 39.2 months [95% CI, 34.5‐49.1 months]; P = .048) had decreased OS. TP53 alterations were independently associated with OS in a multivariate analysis (hazard ratio, 1.54; 95% CI, 1.01‐2.33; P = .042). Individuals with germline alterations in homologous recombination deficiency (HRD) genes had improved OS in comparison with those without them (median, not reached vs 37.0 months; 95% CI, 33.0‐49.8 months; P = .035). Conclusions: In patients with resected PDAC, genomic alterations in KRAS and TP53 are associated with worse outcomes, whereas alterations in HRD genes are associated with a favorable prognosis. Further studies are needed to better define these alterations as biomarkers in resected PDAC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.33038

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 76

Metadata

Authors
McIntyre, C. A., Lawrence, S. A., Richards, A. L., Chou, J. F., Wong, W., Capanu, M., Berger, M. F., Donoghue, M. T. A., Yu, K. H., Varghese, A. M., Kelsen, D. P., Park, W., Balachandran, V. P., Kingham, T. P., D’Angelica, M. I., Drebin, J. A., Jarnagin, W. R., Iacobuzio‐Donahue, C. A., Allen, P. J., & O’Reilly, E. M.
Venue
Cancer
Publisher
Wiley
Published
2020-06-23
Volume
126
Issue
17
Pages
3939-3949
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W3036064083
Cited by
76
References
18
FWCI
3.45
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. https://app.cochat.ai/papers/10.1002/cncr.33038
The paper
McIntyre, C. A., Lawrence, S. A., Richards, A. L., Chou, J. F., Wong, W., Capanu, M., Berger, M. F., Donoghue, M. T. A., Yu, K. H., Varghese, A. M., Kelsen, D. P., Park, W., Balachandran, V. P., Kingham, T. P., D’Angelica, M. I., Drebin, J. A., Jarnagin, W. R., Iacobuzio‐Donahue, C. A., Allen, P. J., & O’Reilly, E. M. (2020). Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer. https://doi.org/10.1002/cncr.33038

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.